Literature DB >> 19036938

Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.

Shawn R Lockhart1, Shawn A Messer, Michael A Pfaller, Daniel J Diekema.   

Abstract

Candida fermentati isolates make up a small percentage of the clinical isolates of the Candida guilliermondii complex and have a global distribution pattern. With the exception that the MICs of micafungin were significantly lower, the calculated average MICs for C. fermentati were not significantly different from those for C. guilliermondii.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19036938      PMCID： PMC2620835          DOI： 10.1128/JCM.01889-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii.

Authors:  Lisa Lan; Jianping Xu
Journal:  Microbiology       Date:  2006-05       Impact factor: 2.777

2.  Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil.

Authors:  Eduardo Alexandrino Servolo Medeiros; Timothy J Lott; Arnaldo Lopes Colombo; Patrício Godoy; Ana Paula Coutinho; Monica Santos Braga; Marcio Nucci; Mary E Brandt
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

3.  Candida fermentati from HIV patients in Chennai, South India.

Authors:  K Umamaheswari; Thangam Menon
Journal:  Int J Infect Dis       Date:  2008-07-22       Impact factor: 3.623

4.  Clinical isolates of Candida guilliermondii include Candida fermentati.

Authors:  R M San Millán; L C Wu; I F Salkin; P F Lehmann
Journal:  Int J Syst Bacteriol       Date:  1997-04

5.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

6.  Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999.

Authors:  Manuel Cuenca-Estrella; Laura Rodero; Guillermo García-Effrón; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

7.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079
View more
  17 in total

1.  Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi.

Authors:  N Esther Babady; Edwin Miranda; Kathleen A Gilhuley
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

2.  Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.

Authors:  Noura Al-Sweih; Suhail Ahmad; Leena Joseph; Seema Khan; Sandhya Vayalil; Rachel Chandy; Ziauddin Khan
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

3.  Development of two molecular approaches for differentiation of clinically relevant yeast species closely related to Candida guilliermondii and Candida famata.

Authors:  Xiaobo Feng; Jingsong Wu; Bo Ling; Xianwei Yang; Wanqing Liao; Weihua Pan; Zhirong Yao
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

4.  Prevalence and distribution profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis responsible for superficial candidiasis in a Chinese university hospital.

Authors:  Xiaobo Feng; Bo Ling; Guimei Yang; Xia Yu; Daming Ren; Zhirong Yao
Journal:  Mycopathologia       Date:  2011-11-19       Impact factor: 2.574

5.  Molecular identification of closely related Candida species using two ribosomal intergenic spacer fingerprinting methods.

Authors:  Muriel Cornet; Boualem Sendid; Chantal Fradin; Claude Gaillardin; Daniel Poulain; Huu-Vang Nguyen
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

6.  Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.

Authors:  Michael A Pfaller; Mariana Castanheira; Daniel J Diekema; Shawn A Messer; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

7.  Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.

Authors:  Laura Judith Marcos-Zambrano; Mireia Puig-Asensio; Felipe Pérez-García; Pilar Escribano; Carlos Sánchez-Carrillo; Oscar Zaragoza; Belén Padilla; Manuel Cuenca-Estrella; Benito Almirante; M Teresa Martín-Gómez; Patricia Muñoz; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

9.  Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

10.  Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.

Authors:  Tatsuro Hirayama; Taiga Miyazaki; Yuka Yamagishi; Hiroshige Mikamo; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue; Yoshitsugu Higashi; Yoshihiro Yamamoto; Muneyoshi Kimura; Hideki Araoka; Shuichi Taniguchi; Yuichi Fukuda; Yumi Matsuo; Akiko Furutani; Kohei Yamashita; Takahiro Takazono; Tomomi Saijo; Shintaro Shimamura; Kazuko Yamamoto; Yoshifumi Imamura; Koichi Izumikawa; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.